Dementia Drug Investigated for Alcohol Withdrawal Treatment
Researchers from the University of Kentucky have found that certain dementia drugs could potentially help alleviate alcohol withdrawal symptoms by decreasing brain inflammation linked to addiction and relapse. The drug in question, known as MW150, targets a specific inflammatory pathway in the brain called p38α MAPK.
Though still awaiting approval, MW150 was created for treating mild to moderate Alzheimer’s disease. It comes at a time when alcohol-related deaths, particularly among women, have surged more than double in recent years.
Experts think that neuroinflammation might play a significant role in the risk of relapse, as well as in long-term neurological issues faced by those with alcohol use disorder. Laboratory and animal studies indicate that MW150 can decrease certain inflammatory markers during withdrawal.
This research, led by neuroinflammation expert Linda Van Erdyk and published in the journal Alcohol, highlights the challenges of treating alcohol use disorder, particularly because relapse rates are notably high during the withdrawal phase. Dr. Caleb Bailey, a co-author, emphasizes that the findings lend “biological plausibility” to the idea that MW150 can mitigate neuroinflammation associated with alcohol withdrawal.
If future studies confirm similar results in live models, this could bolster the case for MW150 as a viable treatment for those experiencing chronic alcohol relapse linked to withdrawal.
Moreover, MW150 and another related drug, neframapimod, are already undergoing clinical trials targeting dementia and other neurodegenerative conditions. Dr. Bailey points out that their existing development for these neurological ailments might make it easier to repurpose them for alcohol-related issues if further studies prove fruitful.
However, it’s essential to mention the limitations of this study, which was constrained to cell cultures and animal models. Dr. Bailey notes that the “dish-based” tests offer limited insight into the complex interactions at a systemic level, indicating a need for more comprehensive studies involving live animals.
Reacting to the study’s implications, Dr. Amy Swift, who wasn’t part of the research, remarked that while tapering drug doses is a commonly recognized first step for treating alcohol use disorder, it rarely has a lasting impact on individuals’ drinking habits. Detoxification alone, she explained, doesn’t cure alcohol use disorder but helps prevent dangerous complications tied to withdrawal.
Dr. Swift suggests that integrating supportive care—especially medications aimed at enhancing brain health—could fill essential gaps in early treatment. She raises an important point: the need to explore whether reducing neuroinflammation might help patients engage more effectively in treatment and positively alter their long-term relationships with alcohol.
In the broader context, Dr. Bailey urges that reducing alcohol intake remains the most effective way to safeguard one’s health, especially since robust pharmacological options to mitigate the negative effects of chronic alcohol consumption are currently lacking. As MW150 and similar compounds are further studied, clarity on their interaction with alcohol will be crucial for patient outcomes.
